Cytel News

Copenhagen, Denmark —ISPOR Europe 2019 —November 05 2019—Cytel Inc. (“Cytel” or the “Company”), the leading provider of innovative analytical software and consulting services to the biopharmaceutical sector, and a portfolio company of New Mountain Capital, today announced that it has acquired MTEK Sciences (“MTEK”) to further expand its advanced real-world analytics (RWA) capabilities.

Cytel Inc., the leading global provider of innovative analytical software and consulting services to the life sciences industry, has announced that the Complex Innovative Trial Design Symposium and East® Training will take place November 6–7 at Alexion’s headquarters in Boston, Massachusetts. The event will bring together industry-leading experts to discuss innovative solutions to pressing challenges including rare disease clinical trials.

Cytel Inc., the leading global provider of analytical solutions to the life sciences industry, today announced that it will launch East On Demand™ at the annual Joint Statistical Meetings (JSM) 2019 (July 27 – August 1, Denver, Colorado). Offered via the cloud and licensed through subscriptions, East On Demand provides statisticians with more flexible access to East, the industry standard software package for the effective design of adaptive and innovative clinical trials.

Cytel Inc., the leading global provider of innovative analytical software and services to the life sciences industry, and Axio Research, a premier provider of biostatistics to pharmaceutical, biotechnology and medical device companies, today announced that they have joined forces to create the largest global biometrics organization focused on delivering advanced analytical solutions for the life sciences industry. The merged business will operate under the Cytel brand, with Axio continuing to provide its renowned data monitoring committee services for clinical trials, as “Axio, a Cytel company.”

Cytel announced the appointment of Joshua Schultz as Chief Executive Officer (CEO) effective January 7th, 2019. He succeeds Joseph Avellone, who acted as Cytel’s interim CEO from March 2018 and will continue to serve on the company’s Board of Directors.

Mr. Schultz is an accomplished leader with a 20-year track record of success in life sciences and clinical research organizations. He joins Cytel from PAREXEL, where he most recently served as an Officer of the company and Senior Vice President for its Access business unit.  

Cytel announced the launch of OK GO, the first commercially available software to underpin quantitative go/no-go decision-making frameworks in clinical trials.  The innovative product helps sponsors make faster, more robust decisions about their products to improve their R&D productivity.  OK GO is the commercial release of custom software originally developed as a collaboration between AstraZeneca and Cytel scientists to enhance the established decision-making framework in AstraZeneca’s early clinical development group.

Cytel has won Best Contract Research Organization( CRO) – Specialist Providers at the 2018 Scrip Awards. The accolade was presented to Cytel at an awards ceremony in London on 28th November 2018. The Scrip Awards acknowledge the pharmaceutical and biotechnology industry’s highest achievers across the value chain. The Best Contract Research Organization – Specialist Providers category highlights the critical role that CROs play in drug development, and particularly commends quality of service and strength of customer relationships. Cytel was selected as the winner by an independent panel of senior industry experts.

Cytel Inc., a global provider of advanced analytical solutions to the pharmaceutical, biotechnology, and medical device industries, today announced the launch of East® version 6.5, further enhancing the most trusted technology platform for designing, monitoring, and simulating adaptive trials.  Since 1995, East has empowered trial sponsors of all sizes to optimize study planning and monitoring efforts, accelerate timelines, and increase their probability of success in clinical development.

Congratulations to Lipopharma and the CLINGLIO project consortium on their recent 6,15M€ grant award by the European Union’s Horizon 2020 program. Led by Lipopharma, the multinational consortium brings together 12 academic and industry organizations from Europe, Israel, and the USA.

Cytel collaborated with Lipopharma and the consortium to create the innovative trial design and provided statistical input for the successful grant application.